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Could HBx Protein Expression Affect Signal Pathway Inhibition 
by Gefitinib or Selumetinib, a MEK Inhibitor, in Hepatocellular 
Carcinoma Cell Lines?
Hepatitis B virus X (HBx) protein has been known to play an important role in development 
of hepatocellular carcinoma (HCC). The aim of this study is to find out whether HBx 
protein expression affects antiproliferative effect of an epidermal growth factor receptor-
tyrosine kinase (EGFR-TK) inhibitor and a MEK inhibitor in HepG2 and Huh-7 cell lines. We 
established HepG2 and Huh-7 cells transfected stably with HBx gene. HBx protein 
expression increased pERK and pAkt expression as well as β-catenin activity in both cells. 
Gefitinib (EGFR-TK inhibitor) inhibited pERK and pAkt expression and β-catenin activity in 
both cells. Selumetinib (MEK inhibitor) reduced pERK level and β-catenin activity but pAkt 
expression was rather elevated by selumetinib in these cells. Reduction of pERK levels was 
much stronger with selumetinib than gefitinib in both cells. The antiproliferative efficacy 
of selumetinib was more potent than that of gefitinib. However, the antiproliferative 
effect of gefitinib, as well as selumetinib, was not different between cell lines with or 
without HBx expression. Signal pathway activation by HBx might not be strong enough to 
attenuate the antiproliferative effect of EGFR-TK inhibitor. Future experiments are needed 
to understand the role of HBx protein expression in HCC treatment using molecular 
targeting agent.
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ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common can-
cer worldwide and a rise in the incidence and mortality from 
HCC has recently been observed in most industrialized coun-
tries (1). At the time of presentation, less than 40% of HCC pa-
tients are eligible for potential curative treatment (2) and, un-
fortunately, conventional systemic chemotherapeutic agents 
such as doxorubicin, 5-fluorouracil and cisplatin do not have 
significant efficacy in HCC, based on data from randomized tri-
als (3). With the progress in the knowledge of tumor biology, 
new targeting therapies blocking specific signal pathway have 
been developed recently in many solid and hematologic malig-
nancies and there is a great need to find out novel targets and 
to develop specific blocking agents to these targets in HCC as 
well. Hepatitis B virus (HBV) infection is a major risk factor for 
the development of HCC and accounts for the high incidence 
of HCC in Asian and African countries including Korea (4, 5). 
Hepatitis B virus X (HBx) protein, which is encoded in HBV open 
reading frame X gene, has been suggested to play an important 
role in the development of HCC in the setting of chronic HBV 
infection (6). Expression of HBx protein in HCC cells results in 
the increased β-catenin activity (7, 8), activation of Ras/Raf/
MEK/ERK pathway (9) and PI3K/Akt pathway (10, 11) which 
are potential targets for developing new therapeutic agents.
  Ras/Raf/MEK/ERK pathway is one of the most critical signal-
ing cascades for liver tumorigenesis (12). This pathway is cen-
tral in cell growth and survival, transducing extracellular signals 
from ligand-bound tyrosine kinase receptors such as epidermal 
growth factor receptor to the cell nucleus through a series of 
specific phosphorylation events that start with the activation of 
Ras. Although EGFR is not commonly overexpressed in HCC 
cells, its continuous activation by ligands such as transforming 
growth factor-α (TGF-α), heparin-binding epidermal growth 
factor or amphiregulin, which are upregulated from the early 
stages of hepatocarcinogenesis, can be of significance for HCC 
development. The inhibitory activity of epidermal growth factor 
receptor tyrosine kinase (EGFR-TK) inhibitor such as gefitinib 
and erlotinib on human HCC cell growth in culture has been 
recently demonstrated (13, 14). These compounds induced cell 
cycle arrest and apoptosis, and erlotinib enhanced chemosen-
sitivity towards cytostatics (14). In addition, in vivo studies have Park YK, et al.  •  Effect of HBx on HCC Inhibition by Gefitinib or Selumetinib
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shown that gefitinib displays antitumoral effects in a rat model 
of chemically induced liver cirrhosis and HCC (15). However, 
this antiproliferative action of gefitinib on HCC cells was suggest-
ed to be effective only when TGF-α/EGFR autocrine loop and 
the following downstream pathway of EGFR are intact in HCC 
cells (16). HBx protein expressed in HBV infected hepatocyte 
was reported to activate MAPK pathways irrespective of EGFR 
activation through Src kinase activation in several in vitro and 
in vivo studies (9, 17). Therefore, for the treatment of HCC’s in 
Asian countries, where HCC is highly prevalent and HBV infec-
tion is the main cause of carcinogenesis in hepatocytes, the an-
tiproliferative efficacy of EGFR-TK inhibitor on HCC cells could 
be limited. On the contrary, downstream pathway inhibitors, 
such as MEK inhibitors could be more appropriate candidates 
for the growth inhibition of HCC cells expressing HBx protein 
and HCC patients infected with HBV in this aspect.
  To confirm this hypothesis, our experiments were aimed to 1) 
establish HCC cell lines which are stably transfected with HBx 
gene, 2) confirm the effect of HBx expression on the several sig-
nal pathways such as Ras/Raf/MEK/ERK, Wnt/β-catenin, and 
PI3K/Akt pathway and, 3) eventually, compare the antiprolifer-
ative efficacy of EGFR-TK inhibitor and MEK inhibitor in these 
cells.
 
MATERIALS AND METHODS
HCC cell lines and HBx gene transfection
Human HCC cell lines (HepG2, Huh-7) were purchased from 
Japanese Collection of Research Bioresources (JCRB). Both cell 
lines were cultured in Dulbecco modified Eagle medium (DMED) 
supplemented with 10% fetal bovine serum, 100 units/mL pen-
icillin and 100 mg/L streptomycin.
  To establish HCC cell lines expressing HBx protein, plasmid 
with HBx gene was transfected into HepG2 and Huh-7 cells us-
ing Lipofectamine 2000 reagent in Opti-MEM (Invitrogen, Carls-
bad, CA, USA) according to the manufacture’s protocol. HBx 
(subtype ayw) expressing plasmid vector (pEG-HBx) and pEG-
FP-N1 (negative control) were kindly provided by Dr. Kyun-Hwan 
Kim (Konkuk University, Seoul, Korea). For stable cell lines, the 
cells were maintained in selective growth medium supplement-
ed with 600 μg/mL G-418 (Sigma, St. Louis, MO, USA) after trans-
fection. The expression of HBx gene was confirmed by reverse 
transcription-polymerase chain reaction (RT-PCR) and immu-
nofluorescence assay.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from cultured cells using RNA Purifi-
cation System Mini Kit (Invitrogen) and cDNA was amplified 
using the Superscript II reverse transcriptase system (Invitro-
gen) and the pfu PCR pre-Mix kit (Bioneer, Daejeon, Korea). The 
HBx gene was amplified using forward 5´-CAT GGC TGC TAG 
GCT GTG CTG-3´ and reverse 5´-GAG ATG ATT AGG CAG AGG 
TGA AAA AG-3´ primers (18). The size of PCR product was 473 
bp for HBx gene. PCR products were loaded on a 1.5% agarose 
gel with ethidium bromide and image was obtained by photo 
image analyzer (Bio Rad, Hercules, CA, USA).
Immunofluorescence staining
Cells were plated in two-chamber glass slides at a density of a 
2.0 × 10
4 cells per well. After 24 hr in culture medium, the cells 
were washed three times with phosphate-buffered saline (PBS) 
and then fixed with 3.5% paraformaldehyde solution. The cells 
were permeabilized with 0.1% Triton X-100 and nonspecific 
binding was blocked with 5% bovine serum albumin in PBS. Sub-
sequently, cells were incubated with the primary monoclonal 
HBx antibody (Chemicon, Temecula, CA, USA) overnight and 
exposed to anti-mouse IgG conjugated Alexa Fluor 546 (Invitro-
gen) in a dark chamber for 1 hr. For the negative controls, other 
slides were incubated with the same buffer without the primary 
monoclonal HBx antibody. All the slides were mounted with 
mounting medium containing DAPI (Vector Laboratories, Bur-
lingame, CA, USA) and viewed under a fluorescence microscope 
(Leica microsystems, Nussloch, GmbH, Germany).
EGFR-TK and MEK inhibitor treatment
Gefitinib (EGFR-TK inhibitor) and selumetinib (AZD6244; MEK 
inhibitor) were kindly provided by AstraZeneca Pharmaceuti-
cals. Stock solutions were prepared at 20 mM in dimethyl sulf-
oxide (Sigma) and stored in aliquots at -20°C. In immunoblot-
ting assay, these inhibitors were treated for 20 hr in each cell 
line before protein collection. In cell proliferation assay, these 
inhibitors were treated from day 0.
Immunoblotting
Cells were lysed in radioimmune precipitation (RIPA) buffer 
(Upstate, NY, USA) supplemented with protease inhibitor. The 
cell lysates were electrophoresed on 10% polyacrylamide gel, 
transferred onto polyvinylidene difluoride membrane (Bio-Rad 
Laboratories) and blotted with appropriate primary and second-
ary antibodies. The signal was detected using ECL reagent kit 
(Biosciences, Buckinghamshire, UK) and exposed to an X-ray 
film. The primary antibody include: anti-pERK (Thr
202/Tyr
204), 
anti-pAKT (Ser
473), anti-β-catenin (all from Cell signaling Tech-
nology Inc., Beverly, MA, USA), anti-β-actin (Sigma). Goat anti-
rabbit IgG antibody conjugated with horseradish peroxidase 
was used as the secondary antibody (Santa Cruz, CA, USA).
Reporter gene assay
Cells were cotransfected over 24 hr using 20 ng TK Renilla-CMV 
and 0.2 µg TCF reporter plasmid (Upstate Biotechnology Inc., 
Lake Placid, NY, USA). Firefly and Renilla luciferase activities 
were quantified using a dual luciferase reporter assay system Park YK, et al.  •  Effect of HBx on HCC Inhibition by Gefitinib or Selumetinib
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(Promega, Madison, WI, USA). Data were expressed as ratios of 
firefly to Renilla luciferase activity. The experiment was repeat-
ed at least three times for each cell line.
Cell proliferation assay
Cell proliferation was measured using the CellTiter 96 Aqueous 
One Solution cell proliferation assay (Promega), on the basis of 
the cellular conversion of the colorimetric reagent MTS (3,4-[5- 
dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sul-
fophenyl]-2H-tetrazolium salt) into soluble formazan by dehy-
drogenase enzymes found only in metabolically active, prolifer-
ating cells. Following each treatment, 20 µL of dye solution was 
added into each well in 96-well plate and incubated for 3 hr. Sub-
sequently, absorbance at 490 nm was measured with an ELISA 
reader (Magellan, TECAN, Austria).
Primary culture of HCC cells
We performed primary culture of HCC cells from surgically ex-
cised HCC tissue. The study protocol was in accordance with 
the ethical guidelines of the 1995 Declaration of Helsinki and 
was approved by the Investigation and Ethics Committee for 
Human Research (protocol No. 2007-0332) at Asan Medical Cen-
ter. An informed consent was obtained from all the patients be-
fore surgical resection. After excision of HCC tissue from patients, 
1 cm
3 of HCC tissue was transferred immediately to Hank’s bal-
anced salt solution (HBSS) free of calcium and magnesium (19). 
The liver was gently dispersed and chopped with surgical knife 
and placed in HBSS containing 0.03% pronase, 0.05% type IV 
collagenase, and 0.01% deoxyribonuclease (DNase, from bo-
vine pancreas) (all from Sigma) for 20 min at 37°C. The result-
ing cell suspension was filtered through a 100 µm–nylon filter 
(Falcon, Becton Dickinson, Franklin Laces, NJ, USA) and cen-
trifuged at 50 g for 2 min at 4°C to pelletize the hepatocytes. The 
pellet was resuspended in DMEM supplemented with 10% fetal 
bovine serum, 100 U/mL penicillin and 100 mg/L streptomycin 
and seeded in uncoated plastic culture dishes (100 mm Petri-
dish, Primaria, Falcon) at ca. 1 × 10
6 cells/mL. The medium was 
replenished 12 and 24 hr after plating and every 48 hr thereafter. 
After over 100 primary cultures, we got the one cell line, which 
grows over 40 passages of culture, and performed cell prolifera-
tion assay with gefitinib or selumetinib in this cell.
Statistical analysis
Statistical analysis was performed using the SPSS statistical pack-
age version 14 (SPSS, Inc., Chicago, IL, USA). Differences be-
tween two groups were analyzed by two-tailed Student’s t-tests 
and P < 0.05 indicated a statistically significant difference.
 
RESULTS
Establishment of HBx protein expressing HCC cell lines
We transfected pEG plasmid containing HBx gene (pEG-HBx) 
into HepG2 and Huh-7 cells and established stably transfected 
cell lines. HBx gene expression was confirmed by RT-PCR in 
these cells (Fig. 1A). This expression of HBx mRNA was stably 
sustained over 20 passages of culture in these cells. We also con-
firmed HBx protein expression in transfected cell lines by im-
munofluorescence staining. DAPI staining indicates the site of 
nucleus and GFP fluorescence showed the transfected HCC 
cells. Compared with vector plasmid transfection, pEG-HBx 
transfected HCC cells showed strong HBx protein expression in 
immunoflurescence staining (Fig. 1B, C).
pEG pEG
HepG2 Huh-7
HBx
pEG-HBx pEG-HBx
A
Fig. 1. Establishment of HBx protein expressing HCC cell lines. RT-PCR with HBx 
primer (A) and immunofluorescence (IF) staining (× 400) of HepG2 (B) and Huh-7 
cells (C) after pEGFP-N1 or pEG-HBx transfection in HepG2 and Huh-7 cells.
× 400 × 400
GFP GFP
HBx HBx
DAPI DAPI
pEG transfection pEG-HBx transfection
B × 400 × 400
GFP GFP
HBx HBx
DAPI DAPI
pEG transfection pEG-HBx transfection
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pERK and pAkt expression in HepG2 and Huh-7 cells and 
β-catenin activity were enhanced in Huh-7 cell by HBx 
transfection
In Huh-7 cells, the expression of pERK was constitutively elevat-
ed and further activated by HBx transfection. HepG2 cells also 
showed the enhancement of pERK expression by HBx transfec-
tion but the expression level was weaker than Huh-7 cells. Treat-
ment of TGF-α activated pERK expression in both cells as previ-
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Fig. 2. pERK and pAkt expression and β-catenin activity changes by gefitinib or selumetinib in HepG2 and Huh-7 cells. Western blotting was performed for pERK, EGFR and 
pMEK in pEGFP-N1 or pEG-HBx transfected HepG2 and Huh-7 cells with or without TGF-α treatment (A). pERK, pAkt, β-catenin expression was also measured after the 
treatment of gefitinib (B) or selumetinib (C) in both cells. β-catenin activity was measured in Huh-7 cells with or without the treatment of gefitinib or selumetinib by TCF reporter 
gene assay (D). *P < 0.001.
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ously reported (Fig. 2A). pAkt expression was also activated by 
HBx transfection and TGF-α treatment in both cell lines (Fig. 2B, 
C). HBx transfection enhanced β-catenin activity significantly 
in Huh-7 cells, which was confirmed by reporter gene assay (P 
< 0.05) (Fig. 2D), but the expression of β-catenin was not affect-
ed by either HBx transfection or TGF-α treatment (Fig. 2B, C).
Effect of gefitinib on the expression of pERK, pAkt, 
β-catenin in HBx transfected HCC cell lines
Gefitinib inhibited effectively HBx transfection and/or TGF-α 
treatment induced pERK and pAkt expression in HepG2 cells. 
Gefitinib also inhibited expression of pERK and pAkt in Huh-7 
cells but this inhibition was not complete. HBx transfected Huh-
7 cells showed stronger expression of pERK than control cells 
even after the treatment of gefitinib (Fig. 2B). β-catenin expres-
sion was not affected by gefitinib treatment in both cell lines 
but β-catenin activity was significantly inhibited by gefitinib in 
Huh-7 cells regardless of HBx transfection (Fig. 2D). 
Effect of selumetinib on the expression of pERK, pAkt, 
β-catenin in HBx transfected HCC cell lines
Selumetinib strongly inhibited the enhancement of pERK ex-
pression by HBx transfection and/or TGF-α treatment in both 
HepG2 and Huh-7 cells. pAkt expression was rather elevated 
after treatment of selumetinib in both cell lines (Fig. 2C). The 
level of β-catenin expression was not changed by selumetinib 
in both cell lines but β-catenin activity was significantly inhibit-
ed by selumetinib regardless of HBx transfection and the sup-
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Fig. 3. Antiproliferative effect of gefitinib in HepG2 and Huh-7 cells. MTS assay was performed in pEGFP-N1 or pEG-HBx transfected HepG2 (A) or Huh-7 cells (B) with or 
without gefitinib.
pression was stronger than gefitinib in Huh-7 cells (Fig. 2D).
Cell proliferation inhibition by gefitinib or selumetinib in 
pEGFP-N1 or pEG-HBx transfected HepG2 and Huh-7 cell 
lines
Gefitinib 10 µM inhibited the growth of HepG2 and Huh-7 cell 
lines effectively regardless of HBx transfection. HBx transfec-
tion did not affect antiproliferative effect of 10 µM gefitinib in 
both cell lines. However, gefitinib 1 µM did not show significant 
growth inhibition in both cell lines irrespective of HBx transfec-
tion (Fig. 3). Selumetinib inhibited the growth of HepG2 and 
Huh-7 cells profoundly in a dose dependent manner. The growth 
inhibition by selumetinib was not influenced by HBx transfec-
tion in either cell line (Fig. 4). However in view of the fact that 
concentrations in excess of 1 µM are required to slow down cell 
growth, these cells can be considered to be resistant to MEK in-
hibition.
Cell proliferation inhibition by gefitinib or selumetinib in 
primary cultured HCC cell line
We performed primary culture with 100 HCC tissues resected 
from HCC patients and one cell line, which came from HCC tis-
sue resected from a female patient with HBV infection, has be-
come established after serial passage. These cells grew stably 
over 50 passages without gross morphological changes. We per-
formed cell viability assay with gefitinib or selumetinib in these 
cells. Gefitinib 10 µM inhibited the growth of primary cultured 
HCC cell line effectively but 1 µM did not show such inhibitory Park YK, et al.  •  Effect of HBx on HCC Inhibition by Gefitinib or Selumetinib
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effect. Selumetinib inhibited the growth of these cells profound-
ly even in a dose of 1 µM (Fig. 5) which therefore seem some-
what more sensitive to selumetinib than either of the established 
cell lines.
 
DISCUSSION
Because conventional cytotoxic chemotherapy has not been 
shown to prolong survival in unrespectable HCC patients (3), 
there is a significant unmet need for the new therapies to pro-
long survival of HCC patients who are not eligible for potential 
curative treatment. With the progress in the knowledge of he-
patocarcinogenesis, several signal pathways, such as Ras/Raf/
MEK/ERK, PI3K/Akt/mTOR, Wnt/β-catenin and vascular en-
dothelial growth factor (VEGF) activity, were explored exten-
sively in HCC cells and many molecular targeting agents which 
inhibit specific step of each pathway were found to have poten-
tial role in the treatment HCC in in vitro or in vivo experiments 
and early phase clinical trials (20). Recently, significant progress 
has been made in the study of molecular targeting agent for HCC. 
Sorafenib, which inhibits both Raf kinase and VEGF receptor, has 
been shown to prolong survival of HCC patients in phase-III 
clinical trial (21). However the partial response rate of sorafenib 
was only 2%; and novel molecular targeting agents or new com-
bination regimens are still necessary in the treatment of HCC.
  EGFR-TK inhibitor (gefitinib) and MEK inhibitor (selumeti-
nib) are other potentially promising agents in HCC treatment 
because EGFR/Ras/Raf/MEK/ERK pathway is one of the most 
critical signaling cascades for hepatocarcinogenesis. In in vitro 
experiments, gefitinib showed anti-proloferative effect in sever-
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al HCC cell lines (13-15) but the growth inhibition was effective 
only when TGF-α/EGFR autocrine loop and the following down-
stream pathway of EGFR are intact in HCC cells (16). Selumetinib 
was reported recently to have antiproliferative effect in HCC 
cell lines in one report (22).
  HBx protein, which is expressed in HCC cells of chronic hep-
atitis B patients, can activate the three signal pathways (7-11). 
Therefore, we postulated that the antiproliferative effect of gefi-
tinib and selumetinib could be different according to the expres-
sion of HBx protein in HCC cells because HBx expressing HCC 
cells could bypass EGFR pathway to activate MEK through HBx/ 
Src kinase activation (9, 17) (Fig. 6). Therefore, in our experiments 
we aimed to find out the effect of HBx transfection on the anti-
proliferative effects of gefitinib and selumetinib in HCC cell lines.
  We established stably HBx transfected HepG2 and Huh-7 cell 
line. In other several reports (8-11), HBx protein expression was 
confirmed with Western blotting band but in our experiment 
the band of this small protein (17 kDa) could not be obtained. 
Instead, we confirmed HBx expression with immunofluores-
cence staining. pERK and pAkt expression and β-catenin activi-
ty were activated by HBx transfection in Huh-7 and to a lesser 
extent in HepG2 cells as in previous reports (7-11). Gefitinib in-
hibited ERK phosphorylation in both cells regardless of HBx 
transfection but, in Huh-7 cells, HBx transfected cells showed 
stronger pERK expression than control cells even after gefitinib 
treatment. In contrast, selumetinib inhibited ERK phosphoryla-
tion profoundly in both HepG2 and Huh-7 cells regardless of 
HBx transfection, which was in accordance with our hypothe-
sis. Regarding pAkt, gefitinib inhibited pAkt expression effec-
tively in both cells regardless of HBx transfection, but treatment 
of selumetinib lead to some increase in the expression of pAkt 
in both cell lines. These findings suggest that the cross-talk be-
tween EGFR/Ras/Raf/MEK/ERK and PI3K/Akt/mTOR path-
way could be in the level of EGFR/Ras/Raf and the antiprolifer-
ative effect of selumetinib on HCC cells could be compensated 
by PI3K/Akt/mTOR pathway activation in these cells. And also, 
gefitinib could have more potent antiproliferative effect by in-
hibiting both EGFR/Ras/Raf/MEK/ERK and PI3K/Akt/mTOR 
pathways in HCC cells. Regarding β-catenin activity, selumetinib 
showed stronger inhibition than gefitinib in both cells regard-
less of HBx transfection.
  According to our hypothesis, we expected that the antiprolif-
erative effect of gefitinib was limited in HCC cell lines transfect-
ed with HBx gene compared with control cells and the antipro-
liferative effect of selumetinib was not affected by HBx transfec-
tion in HCC cells. However, antiproliferative effect of both agents 
was not affected by HBx transfection, indeed both cell lines were 
relatively resistant to selumetinib and gefitinib. So, the effect of 
HBx transfection on each pathway was confirmed respectively 
in our experiments but the functional assay failed to prove our 
hypothesis. Considering the complex network of signal path-
ways (20), there is a possibility that the activation of pERK, pAkt 
and β-catenin by HBx transfection was not strong enough to at-
tenuate the antiproliferative effect of gefitinib and moreover, 
gefitinib could inhibit PI3K/Akt/mTOR pathway as well as EGFR/ 
Ras/Raf/MEK/ERK in our experiment. Further experiments 
with more trial and error will be needed to find out the most ef-
fective targeting agent or combination regimen in the treatment 
of HCC.
  In conclusion, HBx expression enhanced pERK, pAkt and 
β-catenin activity in HepG2 and Huh-7 cell lines. EGFR-TK in-
hibitor could inhibit pERK expression in both HCC cell lines 
but this inhibitory effect was attenuated by HBx expression in 
both cells. However, antiproliferative effect of EGFR-TK inhibi-
tor was not affected by HBx expression in both cell lines, and it 
might be explained by the other hypothesis that the activation of 
signal pathway by HBx transfection could not be strong enough 
to attenuate the antiproliferative effect of gefitinib, or gefitinib 
could show antiproliferative effect by inhibiting both EGFR/Ras/ 
Raf/MEK/ERK and PI3K/Akt/mTOR pathway in HCC cell lines. 
Targeted inhibition of MEK activity by selumetinib may repre-
sent a valuable alternative approach for the treatment of HCC. 
Future experiments will be needed to understand the role of 
HBx protein expression in the treatment of HCC while blocking 
relevant pathway by molecular targeting agent, and to find out 
the most effective targeting agent or combination regimen con-
sidering the complex network of signal pathways in hepatocar-
cinogenesis.
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Fig. 6. Suggested role of HBx protein in signal pathways of hepatocarcinogenesis.
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AUTHOR SUMMARY
Could HBx Protein Expression Affect Signal Pathway Inhibition by Gefitinib or 
Selumetinib, a MEK Inhibitor, in Hepatocellular Carcinoma Cell Lines?
Yoon Kyung Park, Kang Mo Kim, Young-Joo Lee, Ki-Hun Kim, Sung-Gyu Lee, Danbi Lee, Ju Hyun Shim, Young-Suk Lim,  
Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, and Dong Jin Suh
We investigated whether HBx protein expression affects antiproliferative effect of an epidermal growth factor receptor-tyrosine 
kinase (EGFR-TK) inhibitor and a MEK inhibitor in HepG2 and Huh-7 cell lines. HBx protein expression increased pERK and pAkt 
expression as well as β-catenin activity in both cells. Gefitinib (EGFR-TK inhibitor) inhibited pERK and pAkt expression and 
β-catenin activity in both cells. Selumetinib (MEK inhibitor) reduced pERK level and β-catenin activity but pAkt expression was 
rather elevated by selumetinib in these cells. Reduction of pERK levels was much stronger with selumetinib than gefitinib in both 
cells. The antiproliferative efficacy of selumetinib was more potent than that of gefitinib. However, the antiproliferative effect of 
gefitinib and selumetinib was not different between cell lines with or without HBx expression. Signal pathway activation by HBx 
might not be strong enough to attenuate the antiproliferative effect of EGFR-TK inhibitor. 